Literature DB >> 20337924

Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

S M Gadalla1, L R Preiss, M E Eyster, J J Goedert.   

Abstract

Hepatitis C virus (HCV) treatment failure and disease progression are more likely with high HCV-RNA load. Correlates of high HCV-RNA load in individuals with haemophilia are largely unknown. Among 1266 interferon naïve HCV-infected individuals with haemophilia, we compared those with high (> 2 x 10⁶ HCV-RNA copies/mL) to lower viral load, overall and stratifying on HIV co-infection status using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI). Overall, high HCV load was independently associated with longer duration of HCV infection (P(trend)=0.0001), body mass index ≥ 25 kg/m² (OR=1.4, 95% CI=1.1-1.9), and HIV co-infection (OR=1.4, 95% CI=1.0-1.8). Among 795 HIV-negative participants, high HCV-RNA load was associated with older age at HCV acquisition (OR=1.9 for > 15 years vs ≤ 2 years, P(trend)=0.008), and lower AST/platelet ratio (P(trend)=0.01), in addition to longer duration of HCV infection (P(trend)=0.0008), and body mass index ≥ 25 kg/m² (OR=1.6, P=0.005). Among 471 HIV-positive individuals, anti-retroviral therapy (ART) was the only variable associated with high HCV-RNA load (OR=1.8, CI=1.1-2.9 for combination ART; OR=1.8, CI=0.9-3.4, for other ART vs no treatment). High HCV-RNA load with haemophilia is more likely with longer duration of infection, older age at infection, higher body mass index, and antiretroviral therapy. These findings may help identify individuals at increased risk of HCV treatment failure and progression to end-stage liver disease.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20337924      PMCID: PMC2929328          DOI: 10.1111/j.1365-2893.2010.01289.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  40 in total

Review 1.  Natural history of hepatitis C.

Authors:  L B Seeff
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

2.  Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients.

Authors:  D B Brettler; H J Alter; J L Dienstag; A D Forsberg; P H Levine
Journal:  Blood       Date:  1990-07-01       Impact factor: 22.113

3.  Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; K E Sherman; J J Goedert; A Katsoulidou; A Hatzakis
Journal:  J Infect Dis       Date:  1999-05       Impact factor: 5.226

4.  Prevalence of conditions associated with human immunodeficiency and hepatitis virus infections among persons with haemophilia, 2001-2003.

Authors:  J J Goedert
Journal:  Haemophilia       Date:  2005-09       Impact factor: 4.287

5.  Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

Authors:  Carolin Lackner; Gerd Struber; Bernadette Liegl; Sebastian Leibl; Petra Ofner; Csilla Bankuti; Bernd Bauer; Rudolf E Stauber
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

6.  Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

Authors:  Stefan Zeuzem; Moisés Diago; Edward Gane; K Rajender Reddy; Paul Pockros; Daniele Prati; Mitchell Shiffman; Patrizia Farci; Norman Gitlin; Christopher B O'Brien; François Lamour; Pilar Lardelli
Journal:  Gastroenterology       Date:  2004-12       Impact factor: 22.682

7.  Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease.

Authors:  N Kato; O Yokosuka; K Hosoda; Y Ito; M Ohto; M Omata
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; M W Fried; A M Di Bisceglie; J J Goedert
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

9.  Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

Authors:  J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245

10.  Genotypes and virus load in patients with hepatitis C infection.

Authors:  H Hofmann
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

View more
  4 in total

1.  HIV treatment as prevention among people who inject drugs - a re-evaluation of the evidence.

Authors:  Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman
Journal:  Int J Epidemiol       Date:  2017-04-01       Impact factor: 7.196

2.  Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.

Authors:  Daryoush Behzadpour; Abbas Ahmadi Vasmehjani; Seyed Dawood Mousavi Nasab; Nayeb Ali Ahmadi; Rasoul Baharlou
Journal:  Pathog Glob Health       Date:  2016-11-10       Impact factor: 2.894

Review 3.  The involvement of microRNAs in HCV and HIV infection.

Authors:  Nicky Joshi; Madhuri Chandane Tak; Anupam Mukherjee
Journal:  Ther Adv Vaccines Immunother       Date:  2022-07-05

Review 4.  MicroRNAs, hepatitis C virus, and HCV/HIV-1 co-infection: new insights in pathogenesis and therapy.

Authors:  Archana Gupta; Gokul Swaminathan; Julio Martin-Garcia; Sonia Navas-Martin
Journal:  Viruses       Date:  2012-10-26       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.